

BRUKER BIOSCIENCES CORP

Form 8-K

July 22, 2004

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 22, 2004**

BRUKER BIOSCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

000-30833

(Commission
File Number)

04-3110160

(IRS Employer
Identification No.)

**40 Manning Road
Billerica, MA 01821**

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(978) 663-3660**

Item 12. Results of Operations and Financial Condition

On July 22, 2004, Bruker BioSciences Corporation announced the resignation of its Chief Financial Officer. A copy of the related press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

The information provided in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BRUKER BIOSCIENCES CORPORATION
(Registrant)

Date: July 22, 2004

By:

/s/ Frank H. Laukien

Frank H. Laukien, Ph.D.

Chairman, President and Chief Executive Officer

Exhibit Index

Number	Description
99.1	Bruker BioSciences Corporation press release dated July 22, 2004.